Profhilo® Structura 2 ml is an HA-based bioremodeling treatment designed to improve skin quality, firmness, and elasticity without adding volume. Powered by IBSA’s hybrid cooperative complexes, it delivers deep hydration and supports tissue remodeling for smoother texture and natural contour definition. Indicated for early to moderate laxity and loss of elasticity, it is commonly used on the lower face, jawline, cheeks, and neck. Protocols typically begin with an initial series followed by maintenance, as advised by a licensed practitioner.
Engineered with IBSA’s hybrid cooperative complexes (HCC) of high- and low-molecular-weight HA, Profhilo® Structura supports dermal remodeling and tissue quality enhancement. It is suitable for patients presenting with reduced elasticity, early to moderate laxity, and visible texture irregularities. Typical treatment areas include the lower face, jawline, cheeks, and neck. A protocol commonly involves an initial series of sessions followed by periodic maintenance, according to practitioner assessment and patient needs.
For use by Trained professionals only. Treatment plans, injection techniques, and intervals should follow the official instructions for use (IFU) and local regulations.
It is used to improve skin quality and firmness via HA-based bioremodeling, addressing elasticity loss, mild to moderate laxity, and uneven texture on the face and neck.
Unlike volumizing fillers, Profhilo® Structura focuses on tissue quality and remodeling with hybrid HA complexes, aiming for global improvement in elasticity, hydration, and texture rather than adding volume.
Common areas include the lower face, jawline, cheeks, and neck. The exact plan is determined by the treating professional.
Protocols vary. Many patients begin with an initial series (e.g., spaced weeks apart) followed by maintenance sessions as advised by the practitioner.
Longevity depends on individual factors (age, skin status, lifestyle) and adherence to maintenance. Your practitioner will tailor the schedule to sustain outcomes.
Combination approaches (e.g., neuromodulators, energy-based devices, or other HA products) may be considered by the practitioner, respecting appropriate sequencing and safety intervals.
Contraindications and precautions are detailed in the IFU. Generally, treatment is avoided in patients with known hypersensitivity to HA, active skin infections at the injection site, or in pregnancy/breastfeeding.
Store and handle according to the manufacturer’s specifications. Use only if packaging is intact and within the labeled expiry date.
